Document Type : Review Articles
Authors
1
Thuriban General Hospital, Ministry of Health, Saudi Arabia
2
Bahar Health Center, , Ministry of Health, Saudi Arabia
3
Directorate of health affairs, Jeddah, , Ministry of Health, Saudi Arabia
4
Alreath hospital, Ministry of Health, Saudi Arabia
5
Aquwayiyah General Hospital, Ministry of Health, Saudi Arabia
6
Judaida Arar Health Center, Ministry of Health, Saudi Arabia
7
Prince Mohammed bin Abdulaziz Hospital, Ministry of Health, Saudi Arabia
8
Al aridh hospital, Ministry of Health, Saudi Arabia
9
Aldar Albeidha First Health Center, Ministry of Health, Saudi Arabia
10
King Salman Hospital, Ministry of Health, Saudi Arabia
11
Durma general hospital, Ministry of Health, Saudi Arabia
12
Alyamama hospital, Ministry of Health, Saudi Arabia
13
Primary CareCenter in Medical supply Abu Arish, Ministry of Health, Saudi Arabia
14
Riyadh Health Cluster 1, Ministry of Health, Saudi Arabia
15
Primary Care Center Hakama Abu Arish, Ministry of Health, Saudi Arabia
16
ALJAZEARH PHC, Ministry of Health, Saudi Arabia
Abstract
Background: Drug metabolism is a complex biochemical process, where cytochrome P450 enzymes (CYPs) play a crucial role in the biotransformation of medications. Variations in these enzymes can influence the pharmacokinetics and pharmacodynamics of drugs, leading to inter-individual differences in drug response. Personalized pharmacotherapy aims to tailor drug treatment based on individual genetic and metabolic profiles to optimize therapeutic outcomes and minimize adverse effects.
Aim: This paper explores the biochemical mechanisms involved in drug metabolism, focusing on the role of cytochromes in drug biotransformation. It also examines how personalized medicine and pharmacometabolomics can enhance drug efficacy and safety in clinical practice.
Methods: A comprehensive review of the literature was conducted to assess the biochemical mechanisms involved in cytochrome-mediated drug metabolism. Studies on cytochrome P450 enzymes and their genetic polymorphisms were analyzed to understand their role in personalized pharmacotherapy. Additionally, the potential applications of pharmacometabolomics in drug therapy optimization were explored.
Results: Cytochrome P450 enzymes are responsible for the oxidative metabolism of many drugs, and variations in their genes can significantly affect drug metabolism rates. For instance, some individuals are slow metabolizers of certain drugs due to genetic variations in CYP genes, leading to an increased risk of toxicity, while others are fast metabolizers, which may result in suboptimal drug efficacy. Pharmacometabolomics, the study of metabolic profiles, can offer insights into these variations, allowing for more precise and individualized treatment strategies. Emerging technologies in genomics and metabolomics offer the potential to predict patient responses to drugs, paving the way for personalized pharmacotherapy.
Conclusion: Personalized pharmacotherapy, empowered by pharmacometabolomics and cytochrome analysis, offers significant promise in optimizing drug therapy. Understanding individual metabolic profiles and cytochrome variations enables clinicians to tailor drug treatments, improving therapeutic outcomes and minimizing adverse effects. The integration of these technologies into pharmacy practice can revolutionize the way medications are prescribed, ensuring more effective and safer treatments for patients.
Keywords
Main Subjects
)
View on SCiNiTO